DOD FY04 Prostate Cancer Research Program (PCRP) Clinical Trial Development Award (CTDA)

The summary for the DOD FY04 Prostate Cancer Research Program (PCRP) Clinical Trial Development Award (CTDA) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DOD FY04 Prostate Cancer Research Program (PCRP) Clinical Trial Development Award (CTDA): The Clinical Trial Award for Phase I and/or Phase II clinical trials, anticipated for release in FY05, will be executed through two separate awards: the Clinical Trial Development Award in FY04 and, pending receipt of funds, the Clinical Trial Award in FY05. Proposals for the first award, the Clinical Trial Development Award, are being requested in this program announcement. Recipients of the Clinical Trial Development Award in FY04 will be required to submit proposals, clinical protocols, and consent forms to compete for the Clinical Trial Award in FY05. However, the FY05 Clinical Trial Award will be open to all eligible applicants with clinical trial proposals relevant to prostate cancer treatment, diagnosis, detection, or prevention. Due to the scope and magnitude of the PCRP Clinical Trial Awards, the Clinical Trial Development Award has been instituted to provide support to establish the necessary collaborations and develop clinical protocols to provide a foundation for investigator-initiated clinical trials. The goal of these awards is to provide a foundation for the rapid execution of Phase I or Phase II clinical trial(s) that will have a major impact on the treatment, diagnosis, detection, or prevention of prostate cancer. As such, they should focus on new interventions and not on the refinements of existing interventions (e.g., optimizing timing or dosage regimens).